GlassScriptPhysician profile
Andrew C Dennison
NPI 1891971149
$249.49
in general payments reported to CMS, 2019-2025
11 companies · $65.79 in 2025
The $65.79 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.81 · 2021: $34.49 · 2022: $25.68 · 2023: $49.72 · 2025: $65.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $115.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $45.88 | 2025 | Zerbaxa |
| Abbvie INC. | $28.21 | 2023 | Botox |
| Merz Pharmaceuticals, LLC | $25.68 | 2022 | |
| Melinta Therapeutics, LLC | $22.16 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $21.51 | 2023 | Dysport |
| Cumberland Pharmaceuticals, INC. | $19.91 | 2025 | Vibativ |
| Lundbeck LLC | $18.06 | 2019 | |
| Saol Therapeutics INC. | $17.89 | 2019 | |
| Allergan, INC. | $17.33 | 2021 | |
| Amgen INC. | $17.16 | 2021 | |
| Greenwich Biosciences, INC. | $15.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Dennison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.